ArticleJournal of diabetes research2019
Unlike PD-L1, PD-1 Is Downregulated on Partial Immune Cells in Type 2 Diabetes.
Article in Journal of diabetes research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 25 citations in OpenAlex.
- A systematic review and meta-analysis on the regulation of programmed cell death-1 on T-cells in type 2 diabetes.Medicine · 2021Pooled it
- Inhibitory Immune Checkpoint Molecule Expression in Clinical Sepsis Studies: A Systematic Review.Critical care medicine · 2020Pooled it
- Immune checkpoints and immunoregulation in metabolic diseases and cancers: pathological mechanisms and therapeutic potential.Signal transduction and targeted therapy · 2026Review
- Myeloid-Derived Suppressor Cells (MDSCs) and Obesity-Induced Inflammation in Type 2 Diabetes.Diagnostics (Basel, Switzerland) · 2024Review
- Impact of inpatient management of hyperglycemia on peripheral T cell markers in patients with type 2 diabetes.Diabetology international · 2024Article
- Safety and clinical efficacy of immune checkpoint inhibitors in advanced gastric cancer in the real world.Journal of cancer research and clinical oncology · 2024Article
- The PD-1/PD-L1 Axis in the Biology of MASLD.International journal of molecular sciences · 2024Review
- Integrated Bioinformatics Analysis Revealed Immune Checkpoint Genes Relevant to Type 2 Diabetes.Diabetes, metabolic syndrome and obesity : targets and therapy · 2024Article
- Low glucose availability potentiates the effects of metformin on model T cell activation and exhaustion markersFrontiers in endocrinology · 2023Article
- EMAP II Expression Is Increased on Peripheral Blood Cells from Non-Hodgkin Lymphoma.Journal of immunology research · 2022Article
- Reduction and exhausted features of T lymphocytes under serological changes, and prognostic factors in COVID-19 progression.Molecular immunology · 2021Article
- Metabolic disease and adverse events from immune checkpoint inhibitors.European journal of endocrinology · 2021Observational
- Novel human immunomodulatory T cell receptors and their double-edged potential in autoimmunity, cardiovascular disease and cancer.Cellular & molecular immunology · 2021Review
- Article
- Pre-Existing Diabetes Limits Survival Rate After Immune Checkpoint Inhibitor Treatment for Advanced Lung Cancer: A Retrospective Study in Japan.Diabetes, metabolic syndrome and obesity : targets and therapy · 2021Article
- Dysfunction of CD8 + PD-1 + T cells in type 2 diabetes caused by the impairment of metabolism-immune axis.Scientific reports · 2020Article
- PD-1 mRNA expression in peripheral blood mononuclear cells as a biomarker for different stages of primary gouty arthritis.Journal of cellular and molecular medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionType 2 diabetes is a worldwide disease which is associated with chronic, low-grade inflammation. The PD-1/PD-L1 pathway has been reported to be a negative regulatory element in immune homeostasis and to be involved in many diseases. MATERIALS AND
methodsPeripheral blood mononuclear cells (PBMCs) were obtained from type 2 diabetes patients (
resultsThe PD-L1 expression on corresponding immune cells has no significant difference between these two groups. We showed the downregulated PD-1 expression in type 2 diabetes patients. The correlation analysis indicated that the PD-1 on NK cells has a positive correlation with insulin and diabetes duration. And an inverse correlation has been shown between the PD-1 expression on monocytes and BMI (body mass index).
conclusionsThe results in this article suggest that PD-1, unlike PD-L1, might participate in the progression of type 2 diabetes. This investigation will provide evidence for the potential immune therapy for T2D.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.